OR WAIT null SECS
Accurately targeted immunotherapies through reliable neoantigen recognition enable personalized medicine development.
Activation and expansion are essential for success in both autologous and allogeneic therapies.
Continuous manufacturing and a quality-by-design development approach are a natural fit.
April 15, 2023
Actions combatting the next pandemic must be diverse, reliable, and sustainable.
Unique solutions are required to protect inherently unstable messenger RNA.
This article reviews a range of techniques available for separative analysis of mRNA therapeutics, their associated impurities, and delivery vehicles.
Considerable efforts have been made over the years to resolve the key issues of stability and delivery of RNA-based therapeutics.
The complexity of the RNA production process creates challenges.
April 14, 2023
FDA has granted fast track designation to Caribou Biosciences for its allogeneic CAR-T cell therapy for relapsed or refractory multiple myeloma.
April 10, 2023
Webinar Date/Time: Friday, April 28, 2023 at 11am EDT | 10am CDT | 8am PDT
April 07, 2023
Lonza and ABL Bio are collaborating on the development and manufacture of bispecific antibody product.
April 04, 2023
Webinar Date/Time: Thursday, May 11th, 2023 at 11am EDT | 8am PDT | 4pm BST | 5pm CEST
April 03, 2023
Webinar Date/Time: Tue, May 23, 2023 11:00 AM EDT